Utility of blue-light cystoscopy and tumor-informed ctDNA for management of recurrent high-risk NMIBC with prostatic urethral involvement: A case report

Non-muscle-invasive bladder cancer (NMIBC) with prostatic urethral involvement (PUI) is rare and difficult to manage, especially after intravesical therapy or pelvic radiation. We report a 78-year-old man with recurrent high-risk NMIBC and PUI after bacillus Calmette-Guérin and mitomycin C. Blue-light cystoscopy (BLC) during restaging identified additional carcinoma in situ and high-grade T1 disease not seen with white light. Histopathology showed no stromal invasion, and tumor-informed circulating tumor DNA (ctDNA) testing was negative, indicating no molecular residual disease. Despite favorable findings, the patient elected radical cystectomy, which revealed no residual tumor. This case highlights the complementary roles of BLC and ctDNA.

Authors

Institutions

Publication Details

Journal
Urology Case Reports
Published
2026-01-27
DOI
https://doi.org/10.1016/j.eucr.2026.103362
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Utility of blue-light cystoscopy and tumor-informed ctDNA for management of recurrent high-risk NMIBC with prostatic urethral involvement: A case report

Saum Ghodoussipour, Vignesh T. Packiam, Jennifer Sykes, Mahdi Hemmati Ghavshough et al.
Urology Case Reports
Bladder and Urothelial Cancer Treatments
article

Utility of blue-light cystoscopy and tumor-informed ctDNA for management of recurrent high-risk NMIBC with prostatic urethral involvement: A case report

Saum Ghodoussipour, Vignesh T. Packiam, Jennifer Sykes, Mahdi Hemmati Ghavshough, Melinda Z. Fu, Disha Patel
article en

Abstract

Non-muscle-invasive bladder cancer (NMIBC) with prostatic urethral involvement (PUI) is rare and difficult to manage, especially after intravesical therapy or pelvic radiation. We report a 78-year-old man with recurrent high-risk NMIBC and PUI after bacillus Calmette-Guérin and mitomycin C. Blue-light cystoscopy (BLC) during restaging identified additional carcinoma in situ and high-grade T1 disease not seen with white light. Histopathology showed no stromal invasion, and tumor-informed circulating tumor DNA (ctDNA) testing was negative, indicating no molecular residual disease. Despite favorable findings, the patient elected radical cystectomy, which revealed no residual tumor. This case highlights the complementary roles of BLC and ctDNA.

Urology Case ReportsVol. 65
Rutgers, The State University of New Jersey (US)
Good health and well-being
Openalex Percentile: Top 77%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Utility of blue-light cystoscopy and tumor-informed ctDNA for management of recurrent high-risk NMIBC with prostatic urethral involvement: A case report — Saum Ghodoussipour, Vignesh T. Packiam, et al. · Urology Case Reports (2026) | TGRS Research Map | TGRS